Cargando…
Modelling amyotrophic lateral sclerosis: progress and possibilities
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that primarily affects the motor system and presents with progressive muscle weakness. Most patients survive for only 2-5 years after disease onset, often due to failure of the respiratory muscles. ALS is a familial disease in ∼10%...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451175/ https://www.ncbi.nlm.nih.gov/pubmed/28468939 http://dx.doi.org/10.1242/dmm.029058 |
_version_ | 1783240127986794496 |
---|---|
author | Van Damme, Philip Robberecht, Wim Van Den Bosch, Ludo |
author_facet | Van Damme, Philip Robberecht, Wim Van Den Bosch, Ludo |
author_sort | Van Damme, Philip |
collection | PubMed |
description | Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that primarily affects the motor system and presents with progressive muscle weakness. Most patients survive for only 2-5 years after disease onset, often due to failure of the respiratory muscles. ALS is a familial disease in ∼10% of patients, with the remaining 90% developing sporadic ALS. Over the past decade, major advances have been made in our understanding of the genetics and neuropathology of ALS. To date, around 20 genes are associated with ALS, with the most common causes of typical ALS associated with mutations in SOD1, TARDBP, FUS and C9orf72. Advances in our understanding of the genetic basis of ALS have led to the creation of different models of this disease. The molecular pathways that have emerged from these systems are more heterogeneous than previously anticipated, ranging from protein aggregation and defects in multiple key cellular processes in neurons, to dysfunction of surrounding non-neuronal cells. Here, we review the different model systems used to study ALS and discuss how they have contributed to our current knowledge of ALS disease mechanisms. A better understanding of emerging disease pathways, the detrimental effects of the various gene mutations and the causes underlying motor neuron denegation in sporadic ALS will accelerate progress in the development of novel treatments. |
format | Online Article Text |
id | pubmed-5451175 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Company of Biologists Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-54511752017-06-01 Modelling amyotrophic lateral sclerosis: progress and possibilities Van Damme, Philip Robberecht, Wim Van Den Bosch, Ludo Dis Model Mech Review Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that primarily affects the motor system and presents with progressive muscle weakness. Most patients survive for only 2-5 years after disease onset, often due to failure of the respiratory muscles. ALS is a familial disease in ∼10% of patients, with the remaining 90% developing sporadic ALS. Over the past decade, major advances have been made in our understanding of the genetics and neuropathology of ALS. To date, around 20 genes are associated with ALS, with the most common causes of typical ALS associated with mutations in SOD1, TARDBP, FUS and C9orf72. Advances in our understanding of the genetic basis of ALS have led to the creation of different models of this disease. The molecular pathways that have emerged from these systems are more heterogeneous than previously anticipated, ranging from protein aggregation and defects in multiple key cellular processes in neurons, to dysfunction of surrounding non-neuronal cells. Here, we review the different model systems used to study ALS and discuss how they have contributed to our current knowledge of ALS disease mechanisms. A better understanding of emerging disease pathways, the detrimental effects of the various gene mutations and the causes underlying motor neuron denegation in sporadic ALS will accelerate progress in the development of novel treatments. The Company of Biologists Ltd 2017-05-01 /pmc/articles/PMC5451175/ /pubmed/28468939 http://dx.doi.org/10.1242/dmm.029058 Text en © 2017. Published by The Company of Biologists Ltd http://creativecommons.org/licenses/by/3.0This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. |
spellingShingle | Review Van Damme, Philip Robberecht, Wim Van Den Bosch, Ludo Modelling amyotrophic lateral sclerosis: progress and possibilities |
title | Modelling amyotrophic lateral sclerosis: progress and possibilities |
title_full | Modelling amyotrophic lateral sclerosis: progress and possibilities |
title_fullStr | Modelling amyotrophic lateral sclerosis: progress and possibilities |
title_full_unstemmed | Modelling amyotrophic lateral sclerosis: progress and possibilities |
title_short | Modelling amyotrophic lateral sclerosis: progress and possibilities |
title_sort | modelling amyotrophic lateral sclerosis: progress and possibilities |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451175/ https://www.ncbi.nlm.nih.gov/pubmed/28468939 http://dx.doi.org/10.1242/dmm.029058 |
work_keys_str_mv | AT vandammephilip modellingamyotrophiclateralsclerosisprogressandpossibilities AT robberechtwim modellingamyotrophiclateralsclerosisprogressandpossibilities AT vandenboschludo modellingamyotrophiclateralsclerosisprogressandpossibilities |